
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025
Description
DelveInsight’s, “Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Glucagon-Like Peptide (GLP) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glucagon-Like Peptide (GLP) Agonist: Overview
Glucagon-Like Peptide (GLP) agonists are a class of medications primarily used in the treatment of type 2 diabetes mellitus. They mimic the action of endogenous GLP-1, a hormone secreted by the intestine in response to food intake. GLP-1 plays a crucial role in regulating glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release, both of which help to lower blood sugar levels.
Several types of GLP-1 receptor agonists are available, each with unique formulations and dosing regimens. Exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are among the most commonly prescribed GLP-1 agonists. These medications are typically administered via subcutaneous injection, with dosing frequency ranging from once-daily to once-weekly injections. Such convenience in dosing improves patient adherence and may contribute to better treatment outcomes.
Glucagon-Like Peptide (GLP) agonists, notably GLP-1 receptor agonists, are pivotal therapeutic targets in type 2 diabetes and obesity management due to their multifaceted effects. They enhance glucose-dependent insulin secretion while inhibiting glucagon release, promoting glycemic control without hypoglycemia. Additionally, GLP-1 agonists curb appetite, foster weight loss, and demonstrate cardiovascular benefits, including reduced major adverse cardiovascular events (MACE). These agents may also preserve pancreatic beta cell function, improve liver health in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and potentially offer neuroprotective and renoprotective effects. With convenient dosing and potential for combination therapies, GLP-1 agonists stand as promising interventions across various metabolic and neurological conditions, reflecting their substantial clinical significance.
""Glucagon-Like Peptide (GLP) Agonist- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glucagon-Like Peptide (GLP) Agonist pipeline landscape is provided which includes the disease overview and Glucagon-Like Peptide (GLP) Agonist treatment guidelines. The assessment part of the report embraces, in depth Glucagon-Like Peptide (GLP) Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glucagon-Like Peptide (GLP) Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Glucagon-Like Peptide (GLP) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucagon-Like Peptide (GLP) Agonist Emerging Drugs
Further product details are provided in the report……..
Glucagon-Like Peptide (GLP) Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Glucagon-Like Peptide (GLP) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Glucagon-Like Peptide (GLP) Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucagon-Like Peptide (GLP) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucagon-Like Peptide (GLP) Agonist drugs.
Glucagon-Like Peptide (GLP) Agonist Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Glucagon-Like Peptide (GLP) Agonist: Overview
Glucagon-Like Peptide (GLP) agonists are a class of medications primarily used in the treatment of type 2 diabetes mellitus. They mimic the action of endogenous GLP-1, a hormone secreted by the intestine in response to food intake. GLP-1 plays a crucial role in regulating glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release, both of which help to lower blood sugar levels.
Several types of GLP-1 receptor agonists are available, each with unique formulations and dosing regimens. Exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are among the most commonly prescribed GLP-1 agonists. These medications are typically administered via subcutaneous injection, with dosing frequency ranging from once-daily to once-weekly injections. Such convenience in dosing improves patient adherence and may contribute to better treatment outcomes.
Glucagon-Like Peptide (GLP) agonists, notably GLP-1 receptor agonists, are pivotal therapeutic targets in type 2 diabetes and obesity management due to their multifaceted effects. They enhance glucose-dependent insulin secretion while inhibiting glucagon release, promoting glycemic control without hypoglycemia. Additionally, GLP-1 agonists curb appetite, foster weight loss, and demonstrate cardiovascular benefits, including reduced major adverse cardiovascular events (MACE). These agents may also preserve pancreatic beta cell function, improve liver health in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and potentially offer neuroprotective and renoprotective effects. With convenient dosing and potential for combination therapies, GLP-1 agonists stand as promising interventions across various metabolic and neurological conditions, reflecting their substantial clinical significance.
""Glucagon-Like Peptide (GLP) Agonist- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glucagon-Like Peptide (GLP) Agonist pipeline landscape is provided which includes the disease overview and Glucagon-Like Peptide (GLP) Agonist treatment guidelines. The assessment part of the report embraces, in depth Glucagon-Like Peptide (GLP) Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glucagon-Like Peptide (GLP) Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glucagon-Like Peptide (GLP) Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Glucagon-Like Peptide (GLP) Agonist.
This segment of the Glucagon-Like Peptide (GLP) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucagon-Like Peptide (GLP) Agonist Emerging Drugs
- Survodutide: Boehringer Ingelheim
- HRS9531: Fujian Shengdi Pharmaceutical
- MK-6024: Merck
- XW014: Sciwind
Further product details are provided in the report……..
Glucagon-Like Peptide (GLP) Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Glucagon-Like Peptide (GLP) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Glucagon-Like Peptide (GLP) Agonist
- There are approx. 60+ key companies which are developing the therapies for Glucagon-Like Peptide (GLP) Agonist. The companies which have their Glucagon-Like Peptide (GLP) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Glucagon-Like Peptide (GLP) Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucagon-Like Peptide (GLP) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucagon-Like Peptide (GLP) Agonist drugs.
Glucagon-Like Peptide (GLP) Agonist Report Insights
- Glucagon-Like Peptide (GLP) Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Glucagon-Like Peptide (GLP) Agonist drugs?
- How many Glucagon-Like Peptide (GLP) Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glucagon-Like Peptide (GLP) Agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucagon-Like Peptide (GLP) Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glucagon-Like Peptide (GLP) Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sciwind
- Boehringer Ingelheim
- Merck
- Eccogene
- Suzhou Alphamab Co., Ltd.
- Regor Pharmaceuticals
- Eli Lilly and Company
- Neuraly
- Carmot Therapeutics
- XW014
- Survodutide
- MK-6024
- ECC5004
- KN056
- RGT001-075
- Tirzepatide
- CT 388
- Pegylated exenatide
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Glucagon-Like Peptide (GLP) Agonist: Overview
- Introduction
- Mechanism of Action
- Structure
- Function
- FDA Approved Glucagon-Like Peptide (GLP) Agonist
- Glucagon-Like Peptide (GLP) Agonist as a therapeutic target
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Indication
- Assessment by Stage and Indication
- Glucagon-Like Peptide (GLP) Agonist– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Survodutide: Boehringer Ingelheim
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MK-6024: Merck
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- XW014: Sciwind
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Glucagon-Like Peptide (GLP) Agonist Key Companies
- Glucagon-Like Peptide (GLP) Agonist Key Products
- Glucagon-Like Peptide (GLP) Agonist- Unmet Needs
- Glucagon-Like Peptide (GLP) Agonist- Market Drivers and Barriers
- Glucagon-Like Peptide (GLP) Agonist- Future Perspectives and Conclusion
- Glucagon-Like Peptide (GLP) Agonist Analyst Views
- Glucagon-Like Peptide (GLP) Agonist Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.